✨
AI Summary
- Oral icotrokinra shows sustained psoriasis clearance over 112 weeks.
- First oral IL-23 receptor antagonist demonstrates no new safety signals.
- Data presented on sustained clearance for scalp, genital, and hand/foot psoriasis.
Guests on This Episode
AB
Andrew Blauvelt
researcher · 1 podcast appearance
LG
Linda Stein Gold
2 podcast appearances